In patients with previously treated inoperable or metastatic HR-positive/HER2-negative breast cancer, those who received datopotamab and deruxtecan reported a slower time to functional deterioration and symptoms compared with a group that received chemotherapy, according to recent research from the 2024 ASCO Annual Meeting. 

Sonia Pernas, MD, PhD, of the Institut Català d'Oncologia in Barcelona, and colleagues analyzed patient-reported outcomes from the phase 3 TROPION-Breast01 study of patients with previously treated inoperable or metastatic HR+/HER2- breast cancer who received 6 mg per kg of datopotamab-deruxtecan every 3 weeks (n = 365) or the investigator’s choice of chemotherapy (n = 367), which consisted of eribulin, vinorelbine, capecitabine, and gemcitabine. 

The researchers analyzed patient-reported outcomes that included the European Organisation For Research And Treatment Of Cancer Core Quality of Life questionnaire as a secondary outcome, which measured the time to deterioration of global health status and/or quality of life (GHS/QoL), physical functioning, and pain. Overall, 82.5% of patients completed the patient-reported outcome questionnaires across all treatment groups. 

The results showed a median time to first deterioration of GHS/QoL of 3.4 months in the datopotamab-deruxtecan group compared with 2.1 months in the chemotherapy group, a median time to first deterioration of physical functioning of 5.6 months vs 3.5 months, and a median time to first deterioration of pain of 3.5 months vs 2.8 months.  

In a sensitivity analysis, the median time to confirmed deterioration for GHS/QoL in the datopotamab-deruxtecan group was 9 months compared with 4.8 months in the chemotherapy group, a median time to confirmed deterioration for physical functioning of 12.5 months vs 6.2 months, and a median time to confirmed deterioration for pain of 9 months vs 5.5 months. The researchers noted that there were similar adverse events reported by patients as seen by clinicians, and treatment tolerability was similar between groups. 

“Patient-reported outcome data complement the improvement in efficacy and manageable safety profile demonstrated with datopotamab-deruxtecan vs investigator’s choice of chemotherapy in the primary analysis, supporting datopotamab-deruxtecan as a potential new, well tolerated therapeutic option in this setting.” 

- Sonia Pernas, MD, PhD, head of the breast cancer unit-medical oncology department at the Institut Català d'Oncologia, Barcelona. 

-- 

References: 

https://meetings.asco.org/abstracts-presentations/233640 

https://clinicaltrials.gov/study/NCT05104866 

Disclosures: Some authors declared financial ties to drugmakers. See full study for details. TROPION-Breast01 is being supported by AstraZeneca and Daiichi-Sankyo. 

Disclaimer: Narration was created using Elevenlabs AI text-to-voice tools and reviewed by MD /alert editorial staff. 

Photo Credit: Getty Images. 

By Jeff Craven, MD /alert Contributor